[HTML][HTML] Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3 …
…, B Ganneru, S Prasad, D Das, D Raju… - The Lancet Infectious …, 2021 - thelancet.com
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 μg or 6 μg)
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
formulated with a toll-like receptor 7/8 agonist molecule (IMDG) adsorbed to alum (Algel). We …
[HTML][HTML] Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants
…, B Ganneru, S Reddy, H Jogdand, D Raju… - Scientific reports, 2022 - nature.com
This is a comprehensive report on immunogenicity of COVAXIN ® booster dose against
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …
ancestral and Variants of Concern (VOCs) up to 12 months. It is well known that neutralizing …
Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of …
…, V Sarangi, B Ganneru, S Prasad, D Das, D Raju… - medRxiv, 2020 - medrxiv.org
Background BBV152 is a whole-virion inactivated SARS-CoV-2 vaccine (3 µg or 6 µg)
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
formulated with a Toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG). Earlier, …
[HTML][HTML] Persisting antibody responses to Vi polysaccharide–tetanus toxoid conjugate (Typbar TCV®) vaccine up to 7 years following primary vaccination of children< …
KM Vadrevu, D Raju, S Rani, S Reddy, V Sarangi… - Vaccine, 2021 - Elsevier
Background Serum IgG anti-Vi titers attained by 327 children 6–23 months of age immunized
with Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®), of whom 193/327 …
with Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®), of whom 193/327 …
Biogenic green synthesis of monodispersed gum kondagogu (Cochlospermum gossypium) iron nanocomposite material and its application in germination and growth of mung …
D Raju, UJ Mehta, SR Beedu - IET nanobiotechnology, 2016 - Wiley Online Library
An eco‐friendly green and one‐pot synthesis of highly monodispersed iron (Fe) nanoparticles
(NPs) by using a natural biopolymer, gum kondagogu (GK) as reducing and capping …
(NPs) by using a natural biopolymer, gum kondagogu (GK) as reducing and capping …
Proximate, mineral composition and antioxidant activity of traditional small millets cultivated and consumed in Rayalaseema region of south India
…, CV Ratnavathi, J Ajani, D Raju… - Journal of the …, 2018 - Wiley Online Library
BACKGROUND Millets are a diverse group of small seeded grasses, widely grown around
the world as cereal foods. This communication details the proximate, mineral profile and …
the world as cereal foods. This communication details the proximate, mineral profile and …
Persistence of immunity and impact of a third (booster) dose of an inactivated SARS-CoV-2 vaccine, BBV152; a phase 2, double-blind, randomised controlled trial
KM Vadrevu, B Ganneru, S Reddy, H Jogdand, D Raju… - MedRxiv, 2022 - medrxiv.org
Background Neutralising antibody responses to SARS-CoV-2 vaccines have been reported
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …
to decline within 6 months of vaccination, particularly against Variants of Concern (VOC). We …
Phytosynthesis of intracellular and extracellular gold nanoparticles by living peanut plant (Arachis hypogaea L.)
D Raju, UJ Mehta, A Ahmad - Biotechnology and applied …, 2012 - Wiley Online Library
Inorganic nanomaterials of different chemical compositions are conventionally synthesized
under harsh environments such as extremes of temperature, pressure, and pH. Moreover, …
under harsh environments such as extremes of temperature, pressure, and pH. Moreover, …
Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or …
KM Vadrevu, R Dugyala, NS Mahantashetti… - Human Vaccines & …, 2022 - Taylor & Francis
We evaluated safety, reactogenicity, and immunogenicity when the WHO-prequalified single-dose
Typhoid Vi-polysaccharide conjugate vaccine, Typbar-TCV®, was administered …
Typhoid Vi-polysaccharide conjugate vaccine, Typbar-TCV®, was administered …
[HTML][HTML] Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies
…, NS Bachtiar, SC Elias, A Goel, R Mishra, R Dugyala… - Biologicals, 2020 - Elsevier
Typhoid vaccines based on protein-conjugated capsular Vi polysaccharide (TCVs) prevent
typhoid in infants and young children. Analysis of the serum anti-Vi IgG response following …
typhoid in infants and young children. Analysis of the serum anti-Vi IgG response following …